Literature DB >> 3319668

The epidemiology of Pseudomonas cepacia in patients with cystic fibrosis.

O C Tablan1, W J Martone, W R Jarvis.   

Abstract

Pseudomonas cepacia has emerged as an important nosocomial pathogen colonizing and infecting the respiratory tract of patients with cystic fibrosis (CF). Although assessment of outcomes associated with P. cepacia colonization has been difficult, controlled studies have shown that colonized patients experience more adverse outcomes compared with those not colonized. In the United States, an increasing trend in national incidence and prevalence of P. cepacia colonization has been shown, but cases have been unevenly distributed in a few centers. These estimates, however, may be biased by intercenter differences in laboratory methods for detecting P. cepacia in patient sputum. The source and mode of transmission of P. cepacia have not been adequately demonstrated, and may vary from center to center. Until further studies elucidate the epidemiology of P. cepacia in patients with CF, it may be prudent for CF centers to consider the use of selective media to isolate P. cepacia from sputa of patients with CF, to conduct investigations of clusters of P. cepacia-colonized patients, and to consider adopting infection control precautions recommended for control of multiply resistant gram negative organisms.

Entities:  

Mesh:

Year:  1987        PMID: 3319668     DOI: 10.1007/BF00145642

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  66 in total

1.  Pseudomonas cepacia strains isolated from water reservoirs of unheated nebulizers.

Authors:  S M Gelbart; G F Reinhardt; H B Greenlee
Journal:  J Clin Microbiol       Date:  1976-01       Impact factor: 5.948

2.  Aerosol polymyxin and pneumonia in seriously ill patients.

Authors:  T W Feeley; G C Du Moulin; J Hedley-Whyte; L S Bushnell; J P Gilbert; D S Feingold
Journal:  N Engl J Med       Date:  1975-09-04       Impact factor: 91.245

3.  Serological types of Diplococcus pneumoniae isolated from the respiratory tract of children with cystic fibrosis and children with other diseases.

Authors:  N Hoiby; G E Hoff; K Jensen; E Lund
Journal:  Scand J Respir Dis       Date:  1976

4.  Newly diagnosed cystic fibrosis in middle and later life.

Authors:  B Hunt; D M Geddes
Journal:  Thorax       Date:  1985-01       Impact factor: 9.139

5.  Bacterial contamination of aerosol solutions used to treat cystic fibrosis.

Authors:  R J Kuhn; A H Lubin; P R Jones; M C Nahata
Journal:  Am J Hosp Pharm       Date:  1982-02

Review 6.  Current status of Pseudomonas cepacia typing systems.

Authors:  C S Rabkin; W R Jarvis; W J Martone
Journal:  Eur J Epidemiol       Date:  1987-12       Impact factor: 8.082

7.  Imipenem/cilastatin in acute pulmonary exacerbations of cystic fibrosis.

Authors:  L R Krilov; J L Blumer; R C Stern; A I Hartstein; B N Iglewski; D A Goldmann
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

8.  Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin.

Authors:  G Nolan; P Moivor; H Levison; P C Fleming; M Corey; R Gold
Journal:  J Pediatr       Date:  1982-10       Impact factor: 4.406

9.  Comparative in-vitro activity of ciprofloxacin against non-fermenters.

Authors:  M O Husson; D Izard; L Bouillet; H Leclerc
Journal:  J Antimicrob Chemother       Date:  1985-04       Impact factor: 5.790

10.  Susceptibility of 324 nonfermentative gram-negative rods to 6 cephalosporins and azthreonam.

Authors:  P C Appelbaum; J Tamim; G A Pankuch; R C Aber
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544

View more
  9 in total

Review 1.  Microorganisms resistant to free-living amoebae.

Authors:  Gilbert Greub; Didier Raoult
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 2.  Cystic fibrosis.

Authors:  T J David
Journal:  Arch Dis Child       Date:  1990-01       Impact factor: 3.791

3.  Epidemiology of pulmonary colonization with Burkholderia cepacia in cystic fibrosis patients. The French Observatoire Burkholderia cepacia Study Group.

Authors:  C Segonds; G Chabanon; G Couetdic; Y Michel-Briand; E Bingen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-10       Impact factor: 3.267

Review 4.  The epidemiology of nosocomial epidemic Pseudomonas cepacia infections.

Authors:  W J Martone; O C Tablan; W R Jarvis
Journal:  Eur J Epidemiol       Date:  1987-09       Impact factor: 8.082

5.  Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom.

Authors:  E J Simmonds; S P Conway; A T Ghoneim; H Ross; J M Littlewood
Journal:  Arch Dis Child       Date:  1990-08       Impact factor: 3.791

6.  Burkholderia cepacia complex in cystic fibrosis in the post-epidemic period: multilocus sequence typing-based approach.

Authors:  Libor Fila; Pavel Dřevínek
Journal:  Folia Microbiol (Praha)       Date:  2017-03-31       Impact factor: 2.099

7.  Genotypic analysis of Burkholderia cepacia isolates from 13 French cystic fibrosis centers.

Authors:  C Segonds; E Bingen; G Couetdic; S Mathy; N Brahimi; N Marty; P Plesiat; Y Michel-Briand; G Chabanon
Journal:  J Clin Microbiol       Date:  1997-08       Impact factor: 5.948

8.  Burkholderia cepacia respiratory tract acquisition: epidemiology and molecular characterization of a large nosocomial outbreak.

Authors:  C F Pegues; D A Pegues; D S Ford; P L Hibberd; L A Carson; C M Raine; D C Hooper
Journal:  Epidemiol Infect       Date:  1996-06       Impact factor: 2.451

9.  Airborne dissemination of Burkholderia (Pseudomonas) cepacia from adult patients with cystic fibrosis.

Authors:  H Humphreys; D Peckham; P Patel; A Knox
Journal:  Thorax       Date:  1994-11       Impact factor: 9.139

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.